Mamtani R - Search Results

1

The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.

Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Moreno BH, Godwin JL, Frenkl T, Sonpavde GP, Mamtani R. Slater RL, et al. Among authors: mamtani r. J Med Econ. 2020 Sep;23(9):967-977. doi: 10.1080/13696998.2020.1770261. Epub 2020 Jun 12. J Med Econ. 2020. PMID: 32412387 Free article.

2

Vinflunine in the treatment of advanced bladder cancer.

Mamtani R, Vaughn DJ. Mamtani R, et al. Expert Rev Anticancer Ther. 2011 Jan;11(1):13-20. doi: 10.1586/era.10.196. Expert Rev Anticancer Ther. 2011. PMID: 21166506 Review.

3

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice.

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R. Parikh RB, et al. Among authors: mamtani r. Oncologist. 2019 Jun;24(6):e397-e399. doi: 10.1634/theoncologist.2019-0039. Epub 2019 Apr 3. Oncologist. 2019. PMID: 30944183 Free PMC article.

4

Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R. Feld E, et al. Among authors: mamtani r. Eur Urol. 2019 Oct;76(4):524-532. doi: 10.1016/j.eururo.2019.07.032. Epub 2019 Jul 28. Eur Urol. 2019. PMID: 31362898 Free PMC article.

5

Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.

Srivastava T, Prabhu VS, Li H, Xu R, Zarabi N, Zhong Y, Pellissier JM, Perini RF, de Wit R, Mamtani R. Srivastava T, et al. Among authors: mamtani r. Eur Urol Oncol. 2020 Oct;3(5):663-670. doi: 10.1016/j.euo.2018.09.012. Epub 2018 Nov 22. Eur Urol Oncol. 2020. PMID: 31412001 Free article.

6

Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.

Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Scott FI, et al. Among authors: mamtani r. J Crohns Colitis. 2020 Jun 19;14(5):575-587. doi: 10.1093/ecco-jcc/jjz212. J Crohns Colitis. 2020. PMID: 31901085 Free PMC article.

7

Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.

Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R. Hale O, et al. Among authors: mamtani r. Clin Genitourin Cancer. 2021 Feb;19(1):e17-e30. doi: 10.1016/j.clgc.2020.07.006. Epub 2020 Jul 16. Clin Genitourin Cancer. 2021. PMID: 32826180 Free article.

8

Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.

Yu S, Mamtani R, O'Hara MH, O'Dwyer PJ, Margalit O, Giantonio BJ, Shmueli E, Reiss KA, Boursi B. Yu S, et al. Among authors: mamtani r. Clin Colorectal Cancer. 2021 Jun;20(2):121-129. doi: 10.1016/j.clcc.2021.01.001. Epub 2021 Jan 22. Clin Colorectal Cancer. 2021. PMID: 33608161

9

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Among authors: mamtani r. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.

10

Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality.

Vader DT, Parikh RB, Li H, Imai K, Hubbard RA, Mamtani R. Vader DT, et al. Among authors: mamtani r. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac050. doi: 10.1093/jncics/pkac050. JNCI Cancer Spectr. 2022. PMID: 35809072 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters